GlassScriptPhysician profile
Daniel N Niknam
NPI 1598262073
$5,871.69
in general payments reported to CMS, 2019-2025
39 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $608 · 2022: $998 · 2023: $1,073 · 2024: $1,367 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,223 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,222.75 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $829.54 | 2021-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Astrazeneca Pharmaceuticals LP | $443.46 | 2021-2025 | Tezspire, Airsupra, Lokelma |
| Actelion Pharmaceuticals US, INC. | $412.47 | 2022-2025 | Uptravi, Opsumit, Opsynvi |
| Novartis Pharmaceuticals Corporation | $401.22 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $295.68 | 2024-2025 | |
| Genzyme Corporation | $268.30 | 2022-2025 | |
| Lundbeck LLC | $261.91 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.76 | 2024-2025 | Ofev, Jardiance |
| Otsuka America Pharmaceutical, INC. | $201.27 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $195.60 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Regeneron Healthcare Solutions, INC. | $195.58 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $179.57 | 2022-2024 | Acthar |
| Pfizer INC. | $178.07 | 2023-2025 | |
| Baxter Healthcare | $168.01 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Janssen Pharmaceuticals, INC | $152.65 | 2022-2024 | Xarelto |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $136.34 | 2023 | |
| Advanced Respiratory, INC | $123.73 | 2021 | |
| Amgen INC. | $109.22 | 2024-2025 | Tepezza |
| Insmed, INC. | $105.75 | 2023-2025 | Arikayce |
| Electromed, INC. | $102.89 | 2024-2025 | Smartvest |
| Sanofi-Aventis U.S. LLC | $94.17 | 2021-2022 | |
| Mannkind Corporation | $89.56 | 2024-2025 | |
| Scilex Pharmaceuticals INC. | $84.21 | 2023-2025 | Ztlido |
| Alexion Pharmaceuticals, INC. | $63.66 | 2021 | |
| Aimmune Therapeutics, INC. | $59.44 | 2025 | Vowst |
| Xeris Pharmaceuticals, INC. | $57.25 | 2021-2025 | Gvoke Hypopen, Keveyis |
| E.R. Squibb & Sons, L.L.C. | $56.85 | 2025 | Cobenfy, Eliquis |
| Sun Pharmaceutical Industries INC. | $53.64 | 2022-2023 | Odomzo |
| Eisai INC. | $51.99 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $45.52 | 2022 | |
| Mylan Specialty L.P. | $39.99 | 2021 | |
| Novo Nordisk INC | $34.77 | 2025 | Ozempic |
| Ani Pharmaceuticals, INC. | $31.53 | 2025 | Purified Cortrophin Gel |
| Sunovion Pharmaceuticals INC. | $30.88 | 2022 | |
| Abbvie INC. | $20.11 | 2024 | |
| Nabriva Therapeutics, Plc | $16.29 | 2021 | |
| Dexcom, INC. | $15.10 | 2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $13.83 | 2023 | Seglentis, Livalo |
| Sumitomo Pharma America, INC. | $11.88 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Niknam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.